Thrivent Financial For Lutherans Neurocrine Biosciences Inc Transaction History

Thrivent Financial For Lutherans

$52.6 Billion
Q3 2024

A detailed history of Thrivent Financial For Lutherans transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Thrivent Financial For Lutherans holds 25,802 shares of NBIX stock, worth $3.24 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

25,802

Previous 46,577 44.6%

Holding current value

$3.24 Million

Previous $6.41 Million 53.63%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	SELL	$114.58 - $153.15 $2.38 Million - $3.18 Million	-20,775 Reduced 44.6%	25,802 $2.97 Million
Q2 2024 Aug 13, 2024	BUY	$130.86 - $143.19 $2.83 Million - $3.1 Million	21,641 Added 86.79%	46,577 $6.41 Million
Q1 2024 May 14, 2024	BUY	$130.4 - $143.74 $50,986 - $56,202	391 Added 1.59%	24,936 $3.44 Million
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $9,970 - $12,479	94 Added 0.38%	24,545 $3.23 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $69,010 - $85,951	-734 Reduced 2.91%	24,451 $2.75 Million
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $27,306 - $31,985	-305 Reduced 1.2%	25,185 $2.38 Million
Q1 2023 May 17, 2023	SELL	$94.11 - $123.02 $450,034 - $588,281	-4,782 Reduced 15.8%	25,490 $2.58 Million
Q4 2022 Feb 08, 2023	BUY	$106.72 - $127.06 $529,224 - $630,090	4,959 Added 19.59%	30,272 $3.62 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $21,903 - $25,658	238 Added 0.95%	25,313 $2.69 Million
Q2 2022 Aug 16, 2022	BUY	$75.79 - $100.07 $21,600 - $28,519	285 Added 1.15%	25,075 $2.44 Million
Q1 2022 May 13, 2022	SELL	$72.45 - $94.81 $16,228 - $21,237	-224 Reduced 0.9%	24,790 $2.32 Million
Q4 2021 Feb 16, 2022	BUY	$79.65 - $106.22 $21,903 - $29,210	275 Added 1.11%	25,014 $2.13 Million
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $31,024 - $35,650	-360 Reduced 1.43%	24,739 $2.37 Million
Q2 2021 Aug 19, 2021	BUY	$89.43 - $102.27 $11,089 - $12,681	124 Added 0.5%	25,099 $2.44 Million
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $2.19 Million - $2.98 Million	24,975 New	24,975 $2.43 Million
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $3.1 Million - $3.86 Million	-35,625 Closed	0 $0
Q3 2020 Nov 10, 2020	SELL	$96.16 - $135.15 $18.5 Million - $26 Million	-192,400 Reduced 84.38%	35,625 $3.43 Million
Q2 2020 Aug 12, 2020	BUY	$85.09 - $130.36 $91,471 - $140,137	1,075 Added 0.47%	228,025 $27.8 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $3,680 - $5,574	-49 Reduced 0.02%	226,950 $19.6 Million
Q4 2019 Feb 13, 2020	BUY	$86.8 - $118.57 $1.78 Million - $2.43 Million	20,464 Added 9.91%	226,999 $24.4 Million
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $517,672 - $626,864	6,176 Added 3.08%	206,535 $18.6 Million
Q2 2019 Aug 13, 2019	BUY	$72.24 - $91.27 $1.07 Million - $1.35 Million	14,752 Added 7.95%	200,359 $16.9 Million
Q1 2019 May 14, 2019	SELL	$69.31 - $91.53 $35.1 Million - $46.3 Million	-506,244 Reduced 73.17%	185,607 $16.4 Million
Q4 2018 Feb 15, 2019	BUY	$68.32 - $124.36 $23 Million - $41.8 Million	336,101 Added 94.48%	691,851 $49.4 Million
Q3 2018 Nov 15, 2018	BUY	$98.88 - $125.85 $10 Million - $12.8 Million	101,517 Added 39.93%	355,750 $43.7 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $213,400 - $300,375	2,834 Added 1.13%	254,233 $25 Million
Q1 2018 May 08, 2018	SELL	$75.88 - $92.43 $27,620 - $33,644	-364 Reduced 0.14%	251,399 $20.8 Million
Q4 2017 Feb 14, 2018	SELL	$58.53 - $77.59 $48,579 - $64,399	-830 Reduced 0.33%	251,763 $19.5 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $12.1 Million - $15.5 Million	252,593	252,593 $15.5 Million

Others Institutions Holding NBIX

# of Institutions

625

Shares Held

94.2M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.

Account

Thrivent Financial For Lutherans Neurocrine Biosciences Inc Transaction History